Andere talen Ascentage Pharma Group International

Aandelen

6855

KYG0519B1023

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:20 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
17,62 ^HKD	+1,85%		+12,23%	-35,46%

25/04	Ascentage Pharma presenteert vier studies op een oncologiebijeenkomst in de VS	MT
09/04	Voorzitter Ascentage Pharma vergroot belang in bedrijf	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ascentage Pharma to Present Four Studies at US Oncology Meet	25/04
Ascentage Pharma Chairman Boosts Stake in Firm	09/04
Ascentage Pharma Group Directors Acquire Company Shares	04/04
Ascentage Pharma Widens Loss by Nearly 5% in 2023	28/03
Ascentage Pharma Announces 2023 Annual Results	28/03
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet	06/03
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting	06/03
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3%	14/02
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA	14/02
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia	14/02
Ascentage Pharma Trustee Buys 100,000 Shares	05/02
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network	17/01
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference	02/01
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib	15/12
Live from ASH 2023, Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR	12/12
Live from ASH 2023, Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib	12/12
Live from ASH 2023, Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%	12/12
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR	11/12
Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 \| Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.	05/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ascentage Pharma Group International

Aandelen

6855

KYG0519B1023

Andere talen

Filters